PD-L1 positive cervical cancer

PD-L1 positive cervical cancer refers to a malignancy of the uterine cervix—most commonly squamous cell carcinoma or adenocarcinoma—characterized by the expression of the immunosuppressive biomarker programmed death-ligand 1 (PD-L1) within the tumor microenvironment

PD-L1 positive cervical cancer refers to a malignancy of the uterine cervix—most commonly squamous cell carcinoma or adenocarcinoma—characterized by the expression of the immunosuppressive biomarker programmed death-ligand 1 (PD-L1) within the tumor microenvironment Pathophysiologically, the binding of PD-L1 to PD-1 receptors on cytotoxic T lymphocytes inhibits T-cell activation and proliferation, promoting immune evasion and accelerated tumor progression

In clinical practice, positivity is typically defined by an immunohistochemical Combined Positive Score (CPS) of 1 or greater, which evaluates membranous PD-L1 staining on neoplastic cells as well as associated tumor-infiltrating mononuclear inflammatory cells

In clinical practice, positivity is typically defined by an immunohistochemical Combined Positive Score (CPS) of 1 or greater, which evaluates membranous PD-L1 staining on neoplastic cells as well as associated tumor-infiltrating mononuclear inflammatory cells

Pathophysiologically, the binding of PD-L1 to PD-1 receptors on cytotoxic T lymphocytes inhibits T-cell activation and proliferation, promoting immune evasion and accelerated tumor progression

This biomarker-defined subtype identifies patient populations with persistent, recurrent, or metastatic cervical malignancies who may benefit from immune checkpoint inhibitor therapy

This biomarker-defined subtype identifies patient populations with persistent, recurrent, or metastatic cervical malignancies who may benefit from immune checkpoint inhibitor therapy